MASCOT : Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV
Safety \& tolerability of FOLFOX4 regimen in the adjuvant treatment of colon cancer in Asian patients
Colonic Neoplasms
DRUG: oxaliplatin
Occurrence of dose-limiting toxicity, from the inform consent signed up to the end of the study
Occurrence of one or more adverse event in a patient, From the Informed Consent Form (ICF) signature to the end of the study|Overall distribution of intensity of adverse events, from the inform consnet signed up to the end of the study|Occurrence of particular adverse events and their intensities, from the inform consent signed up to the end of the study|Percent of patients completing study treatment, from the inform consent signed up to the end of the study|Percent of patients with grade 1, 2 and 3 neuropathy, at 28 days, 6 months and 12 months after last chemotherapy administration.|Percent of intended dose delivered for 5-FU/LV and Oxaliplatin, from the informed consent signed up to the end of the study|Delays in scheduled dosing, During the study conduct|Dose intensity, as expressed as the amount of 5-FU/LV and Oxaliplatin administered divided by the duration of treatment, during the study conduct|•Survival Analysis •Laboratory assay and vital signs ECOG and KPS, during the study conduct|Long term toxicity, during the study conduct
Safety \& tolerability of FOLFOX4 regimen in the adjuvant treatment of colon cancer in Asian patients